Citation

Vakharia PP, Orrell KA, Lee D, Rangel SM, Lund E, Laumann AE, West DP, Nardone B. J. Eur. Acad. Dermatol. Venereol. 2017; 31(10): e463-e464.

Copyright

(Copyright © 2017, John Wiley and Sons)

DOI

10.1111/jdv.14256

PMID

28380251

Abstract

[Abstract unavailable]

Language: en

Keywords

Humans; Risk Factors; United States; Suicide; Retrospective Studies; Adverse Drug Reaction Reporting Systems; United States Food and Drug Administration; Psoriasis; Pharmacovigilance; Product Surveillance, Postmarketing; Anti-Inflammatory Agents, Non-Steroidal; Thalidomide